The impact of HIV-1 subtype on the clinical response on HAART.
Highly active antiretroviral therapy (HAART) has led to a reduction in HIV-related mortality and morbidity. Most patients who have benefited from HAART are infected with HIV-1 subtype B, which predominates in Western Europe, the USA and the rest of the industrialised world. However, most HIV-infecte...
| Main Author: | |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2002
|
| _version_ | 1826292970875256832 |
|---|---|
| author | Frater, J |
| author_facet | Frater, J |
| author_sort | Frater, J |
| collection | OXFORD |
| description | Highly active antiretroviral therapy (HAART) has led to a reduction in HIV-related mortality and morbidity. Most patients who have benefited from HAART are infected with HIV-1 subtype B, which predominates in Western Europe, the USA and the rest of the industrialised world. However, most HIV-infected people live in sub-Saharan Africa, Asia and Eastern Europe. In these areas, subtypes other than B are responsible for the epidemic of HIV-1 infection. This review focuses on the clinical significance of HIV-1 infection with a non-B subtype. The increase in availability of HAART to developing countries together with the large number of HIV-1-infected immigrants being treated in the industrialised world means that data on the clinical response to therapy for non-B HIV-1 infections are becoming of greater practical relevance. If antiretroviral agents, which generally target subtype B, are less efficacious in non-B infections, this will have major clinical implications for therapeutic strategies. Data on drug susceptibility, clinical response and the development of resistance in non-B HIV-1 subtypes are discussed here. |
| first_indexed | 2024-03-07T03:22:54Z |
| format | Journal article |
| id | oxford-uuid:b80809bb-eb77-44b3-a14b-ddcdb4746041 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:22:54Z |
| publishDate | 2002 |
| record_format | dspace |
| spelling | oxford-uuid:b80809bb-eb77-44b3-a14b-ddcdb47460412022-03-27T04:53:04ZThe impact of HIV-1 subtype on the clinical response on HAART.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b80809bb-eb77-44b3-a14b-ddcdb4746041EnglishSymplectic Elements at Oxford2002Frater, JHighly active antiretroviral therapy (HAART) has led to a reduction in HIV-related mortality and morbidity. Most patients who have benefited from HAART are infected with HIV-1 subtype B, which predominates in Western Europe, the USA and the rest of the industrialised world. However, most HIV-infected people live in sub-Saharan Africa, Asia and Eastern Europe. In these areas, subtypes other than B are responsible for the epidemic of HIV-1 infection. This review focuses on the clinical significance of HIV-1 infection with a non-B subtype. The increase in availability of HAART to developing countries together with the large number of HIV-1-infected immigrants being treated in the industrialised world means that data on the clinical response to therapy for non-B HIV-1 infections are becoming of greater practical relevance. If antiretroviral agents, which generally target subtype B, are less efficacious in non-B infections, this will have major clinical implications for therapeutic strategies. Data on drug susceptibility, clinical response and the development of resistance in non-B HIV-1 subtypes are discussed here. |
| spellingShingle | Frater, J The impact of HIV-1 subtype on the clinical response on HAART. |
| title | The impact of HIV-1 subtype on the clinical response on HAART. |
| title_full | The impact of HIV-1 subtype on the clinical response on HAART. |
| title_fullStr | The impact of HIV-1 subtype on the clinical response on HAART. |
| title_full_unstemmed | The impact of HIV-1 subtype on the clinical response on HAART. |
| title_short | The impact of HIV-1 subtype on the clinical response on HAART. |
| title_sort | impact of hiv 1 subtype on the clinical response on haart |
| work_keys_str_mv | AT fraterj theimpactofhiv1subtypeontheclinicalresponseonhaart AT fraterj impactofhiv1subtypeontheclinicalresponseonhaart |